Skip to main content

Advertisement

SpringerLink
Log in

SEOM guidelines for gastrointestinal stromal sarcomas (GIST)

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. These tumours have become a model of multidisciplinary work in oncology: the participation of several specialities (oncologists, pathologists, surgeons, molecular biologists, radiologists and others) has allowed advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first molecular treatment that is efficacious in solid tumours. Following the introduction of this drug, median survival of patients with advanced stage GIST has gone from 18 to more than 60 months. Therapy planning of GIST must be considered within a multidisciplinary context, and it is advisable that it takes place in reference centres for the care of sarcomas and GIST participating in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1

    Article  PubMed  CAS  Google Scholar 

  2. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83

    Article  PubMed  Google Scholar 

  3. Rutkowski P, Bylina E, Wozniak A et al (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896

    Article  PubMed  CAS  Google Scholar 

  4. Gold JS, Gonen M, Gutierrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10:1045–1052

    Article  PubMed  Google Scholar 

  5. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465

    Article  PubMed  Google Scholar 

  6. Edge SB, Byrd DR, Carducci MA, Compton CC (eds) (2009) AJCC Cancer Staging Manual, 7th edn. Springer, New York, NY

    Google Scholar 

  7. Hohenberger P, Ronellenfitsch U, Oladeji O et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97:1854–1859

    Article  PubMed  CAS  Google Scholar 

  8. Martin J, Poveda A, Llombart-Bosch A et al (2005) Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23: 6190–6198

    Article  PubMed  CAS  Google Scholar 

  9. Lau S, Tam KF, Kam CK et al (2004) Imaging of gastrointestinal stromal tumor (GIST). Clin Radiol 59:487–498

    Article  PubMed  CAS  Google Scholar 

  10. Demetri G, Benjamin R, Blanke CD et al (2007) NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST). Update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 5[Suppl 2]: S1–29

    PubMed  Google Scholar 

  11. Lee CM, Chen HC, Leung TK, Chen YY (2004) Gastrointestinal stromal tumor: computed tomographic featrures. World J Gastroenterol 10:2417–2418

    PubMed  Google Scholar 

  12. Casali PG, Jost L, Reichardt P et al; ESMO Guidelines Working Group (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19[Suppl 2]:ii35–38

    Article  PubMed  Google Scholar 

  13. Bensimhon D, Soyer P, Boudiaf M et al (2009) Imaging of gastrointestinal stromal tumors. J Radiol 90:469–480

    Article  PubMed  CAS  Google Scholar 

  14. Miettinen M, Majidi M, Lasota J (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38[Suppl 5]:S39–51

    Article  PubMed  Google Scholar 

  15. Liegl B, Hornick JL, Corless CL, Fletcher CD (2009) Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33:437–446

    Article  PubMed  Google Scholar 

  16. Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet 373:1097–1104

    Article  PubMed  CAS  Google Scholar 

  17. Joensuu H, Eriksson M, Hatrmann J et al (2011) Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 29[Suppl]:LBA1

    Google Scholar 

  18. Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily Imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757

    Article  PubMed  CAS  Google Scholar 

  19. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing Imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  PubMed  CAS  Google Scholar 

  20. Gastrointestinal Stromal Tumor Meta-Analysis Group (2010) Comparison of two doses of Imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247–1253

    Article  Google Scholar 

  21. Le Cesne A, Ray-Coquard I, Nguyen Bui B et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942–949

    Article  PubMed  Google Scholar 

  22. Blay JY, Bonvalo S, Casali O et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16:566–578

    Article  PubMed  Google Scholar 

  23. Demetri D, Van Oosterom AT, Garret CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours after failure of Imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  24. Poveda A, Artigas V, Cervera J et al (2011) Guía de praáctica clínica en los tumores estromales gastrointestinales (GIST): actualización 2010. Cir Esp 86[Suppl 1]:1–21

    Article  Google Scholar 

  25. Poveda A, Artigas V, Cervera J et al (2011) Guía de práctica clÍnica en los tumores estromales gastrointestinales (GIST). Clin Transl Oncol [Suppl 1]:1–20

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, C/ Profesor Beltrán Báguena, 19, ES-46009, Valencia, Spain

    Andrés Poveda, Fernando Rivera & Javier Martín

Authors
  1. Andrés Poveda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Spanish Group for Sarcoma Research (GEIS)

Corresponding author

Correspondence to Andrés Poveda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poveda, A., Rivera, F., Martín, J. et al. SEOM guidelines for gastrointestinal stromal sarcomas (GIST). Clin Transl Oncol 14, 536–540 (2012). https://doi.org/10.1007/s12094-012-0837-8

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0837-8

Keywords

Search

Navigation